… continued the approval of gefitinib because OS benefit was observed in the preplanned
subset analysis in the Asian patients in this study [Citation10]. In 2009, gefitinib was approved by …

… chemotherapy had EGFR mutation but could not get EGFR-TKIs because of the cost associated
with the drug in China, as most patients had to pay out of pocket, in turn limiting its use [3]…

… , versus gefitinib in treatment-naïve patients with advanced … analysis showed that dacomitinib
was superior to gefitinib … independent radiologic central (BIRC) review (hazard ratio [HR…

… Patients with advanced non-… into gefitinib + placebo group and gefitinib + pemetrexed
group. Pemetrexed or placebo was administered on day 1 at a dose of 500 mg/m 2 , and gefitinib …

… gefitinib and erlotinib have both been proven effective for treating advanced non–small cell
lung cancer (… We conducted this meta-analysis to compare their efficacy and safety in treating …

… of advanced non-small-cell lung cancer (NSCLC). This review will summarize and discuss
the clinical results available to date from prospective studies investigating this approach. …

… of gefitinib as first-line treatment, two retrospective analysis … the activity and feasible of gefitinib
treatment in patients aged … weeks after the start of gefitinib treatment. Regardless to toxicity…

… 7 trial, there was no significant PFS and OS benefit when they were comparing afatinib with
gefitinib in older adult participants [12,13]. In the ARCHER 1050 trial, there was significant …

… a meta-analysis comparing the efficacy and safety of gefitinib in combination with chemotherapy
versus gefitinib alone in patients with advanced Non-Small Cell Lung Cancer (NSCLC). …

… growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
… vs gefitinib in advanced non-small cell lung cancer with EGFR mutations. Br J Cancer. 2017; …